Lancet Oncology

Papers
(The H4-Index of Lancet Oncology is 119. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Use of artificial intelligence to enhance detection of nodal metastases801
The future of precise cancer chronotherapeutics777
SABR for operable stage I non-small-cell lung cancer: comparison to surgery696
Patients with cancer in Louisiana denied fertility preservation cover530
Innovation in gynaecological cancer: highlighting global disparities528
Survivorship after neoadjuvant chemotherapy491
Combination immunotherapy in chemotherapy in gastric cancer471
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study460
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia429
US FDA proposes stronger laboratory test oversight424
Correction to Lancet Oncol 2022; 23: 1124–26406
Correction to Lancet Oncol 2021; 22: 309–20381
Medical treatment for active breast cancer brain metastases366
COVID-19 pandemic causes cervical cancer screening crisis366
Enhancing equity and long-term impact assessments in radiotherapy environmental studies358
IVLBCL mimicking VEXAS syndrome339
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies331
The silent malignant mesothelioma epidemic: a call to action315
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy313
The GLOW trial in chronic lymphocytic leukaemia302
Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer301
Dual therapy in metastatic castration-resistant prostate cancer298
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply291
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer290
A new generation of comprehensive precision oncology trials286
Correction to Lancet Oncol 2021; 22: 1081–92281
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, 276
Italy to pass law on the right to be forgotten for cancer survivors276
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer274
Olanzapine for chemotherapy-induced nausea and vomiting control274
Palliative radiotherapy for hepatic cancer pain270
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis266
Concern for cancer drugs in USA–EU tariff war266
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges261
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study256
Study bolsters concerns about US FDA accelerated drug approvals255
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi252
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC251
US Surgeon General calls for cancer warning labels on alcohol249
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t247
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult247
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial240
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, 238
Impact of COVID-19 on cancer care in India: a cohort study234
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial228
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm225
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial222
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma under221
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery221
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial219
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 208
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study206
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries205
Antibody–drug conjugates in acute myeloid leukaemia: more research needed201
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial201
Precision medicine for children with cancer200
CAR T cells for the long run in aggressive B-cell lymphoma200
Focus where it matters: turning insights into advocacy197
Radiotherapy and conflict: from disruption to expansion and hope189
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study188
Decentralised, point-of-care CAR-T for multiple myeloma188
A biobank perspective on use of tissue samples donated by trial participants187
The challenges of cancer care for the LGBTQ+ community183
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer181
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit180
Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis177
A growing vulvar mass in a post-menopausal woman175
Common Sense Oncology: including everyone175
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?174
Gestational trophoblastic neoplasia: one size does not fit all – Authors' reply172
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply172
Essential anticancer medicines for children: defining what matters most for Europe171
Greater price transparency needed for thyroid cancer treatment among US cancer centres170
Lung cancer rates highest among British Bangladeshi men167
Importance of clinical research for the UK's 10-year cancer plan165
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire163
Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis162
Alcohol and the global burden of cancer: what are we missing?160
Balancing clinical benefit and social value: challenges in HTA assessments160
Adjuvant therapy in stage IIIA melanoma - Authors' reply158
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer155
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study152
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:152
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo152
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update151
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti150
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group150
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer148
Lebanon faces critical shortage of drugs147
Cancer on the agenda during IAEA Director General's visit to Chile145
Shortages of essential medications for children with cancer in Colombia143
Radiotherapy with genomic-adjusted radiation dose143
Radiotherapy with genomic-adjusted radiation dose143
GDPR obstructs cancer research data sharing142
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA140
Daratumumab maintenance in patients with myeloma138
Challenges and prospects for cancer treatment in prison settings137
Correction to Lancet Oncol 2023; 24: e242137
2022 ASTRO annual meeting136
Correction to Lancet Oncol 2020; 21: 699–709136
Syrian cancer patients regain treatment access in Türkiye134
Clearing the radiotherapy backlog: innovation to pave the way134
Mantle cell lymphoma: is it time for risk-adapted treatment?134
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus133
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations130
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK130
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis127
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial127
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup127
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra124
WHO reports health service disruptions due to suspensions of aid124
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial124
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study124
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study123
India rolls out HPV vaccination123
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial123
ROAR trial: which treatment is effective after progression?120
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial120
Mozambique takes on cancer burden challenges119
0.12908506393433